Edges in Network
| Network | GSE16446_egf1520 - GSE16446 - SiGN-BN HC+Bootstrap |
| Network Description | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| Node | UBE2L6 |
| Upstream (Parents) |
|---|
| (<<) CD274 → UBE2L6 |
| (<<) CD4 → UBE2L6 |
| (<<) CORO1A → UBE2L6 |
| (<<) HLA-G → UBE2L6 |
| (<<) IRF1 → UBE2L6 |
| (<<) RAC2 → UBE2L6 |
| (<<) RHOF → UBE2L6 |
| (<<) STAT4 → UBE2L6 |
| Downstream (Children) |
|---|
| UBE2L6 → ARSJ (>>) |
| UBE2L6 → BCAR3 (>>) |
| UBE2L6 → CASP7 (>>) |
| UBE2L6 → FAS (>>) |
| UBE2L6 → FNDC4 (>>) |
| UBE2L6 → GBP2 (>>) |
| UBE2L6 → GRK6 (>>) |
| UBE2L6 → HLA-A (>>) |
| UBE2L6 → HLA-F (>>) |
| UBE2L6 → IFITM3 (>>) |
| UBE2L6 → IGFBP2 (>>) |
| UBE2L6 → IL1RN (>>) |
| UBE2L6 → ISG20 (>>) |
| UBE2L6 → ITGB7 (>>) |
| UBE2L6 → MAP3K1 (>>) |
| UBE2L6 → MEX3B (>>) |
| UBE2L6 → MLKL (>>) |
| UBE2L6 → MYO10 (>>) |
| UBE2L6 → PARD6G (>>) |
| UBE2L6 → PARP10 (>>) |
| UBE2L6 → PTAFR (>>) |
| UBE2L6 → PTK2B (>>) |
| UBE2L6 → SCG5 (>>) |
| UBE2L6 → SOCS1 (>>) |
| UBE2L6 → SOD2 (>>) |
| UBE2L6 → STAT1 (>>) |
| UBE2L6 → TNC (>>) |
| UBE2L6 → VIM (>>) |
